TY - JOUR
T1 - Sustained antihypertensive, activity of diltiazem SR
T2 - Double-blind, placebo-controlled study with 24-hour ambulatory blood pressure monitoring
AU - Whelton, A.
AU - Eff, J.
AU - Magner, D. J.
PY - 1992
Y1 - 1992
N2 - A new polymeric matrix technology provides a sustained-release formulation of diltiazem hydrochloride (diltiazem SR) suitable far once-daily therapy. The efficacy and safety af diltiazem SR were evaluated in a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. After a single-blind, placebo lead-in period, 275 patients with mild to moderate essential hypertension were assigned to receive placebo or diltiazem SR 120, 240, 360, or 480 mg once daily for 4 weeks. The efficacy evaluation was based on office and 24-hour ambulatory blood pressure monitoring. Twenty-four hours after the last dose in the 4-week, double-blind treatment period, the mean reduction from baseline in supine diastolic blood pressure ranged from 5.1 to 10.6 mm Hg in the diltiazem SR 120- to 480-mg groups, resulting in a significant linear trend across all treatments (P
AB - A new polymeric matrix technology provides a sustained-release formulation of diltiazem hydrochloride (diltiazem SR) suitable far once-daily therapy. The efficacy and safety af diltiazem SR were evaluated in a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. After a single-blind, placebo lead-in period, 275 patients with mild to moderate essential hypertension were assigned to receive placebo or diltiazem SR 120, 240, 360, or 480 mg once daily for 4 weeks. The efficacy evaluation was based on office and 24-hour ambulatory blood pressure monitoring. Twenty-four hours after the last dose in the 4-week, double-blind treatment period, the mean reduction from baseline in supine diastolic blood pressure ranged from 5.1 to 10.6 mm Hg in the diltiazem SR 120- to 480-mg groups, resulting in a significant linear trend across all treatments (P
UR - http://www.scopus.com/inward/record.url?scp=0026758699&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026758699&partnerID=8YFLogxK
M3 - Article
C2 - 1430300
AN - SCOPUS:0026758699
SN - 0091-2700
VL - 32
SP - 808
EP - 815
JO - Journal of Clinical Pharmacology
JF - Journal of Clinical Pharmacology
IS - 9
ER -